RxSight Third Quarter 2024 Earnings: EPS Beats Expectations
RxSIGHT, INC. RXST | 34.95 | +1.38% |
RxSight (NASDAQ:RXST) Third Quarter 2024 Results
Key Financial Results
- Revenue: US$35.3m (up 59% from 3Q 2023).
- Net loss: US$6.34m (loss narrowed by 49% from 3Q 2023).
- US$0.16 loss per share (improved from US$0.35 loss in 3Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
RxSight EPS Beats Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 35%.
Looking ahead, revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Medical Equipment industry in the US.
The company's shares are down 6.0% from a week ago.
Risk Analysis
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
